Follistatin 344 Research Guide Ireland

Overview

Follistatin 344 (FST344) is not a small synthetic peptide in the same sense as GHRPs or growth hormone secretagogues — it is a recombinant form of follistatin, a naturally occurring activin-binding glycoprotein. Follistatin binds and inhibits myostatin (GDF-8) and activin A, both members of the TGF-beta superfamily and both negative regulators of skeletal muscle growth. FST344 refers to a specific 344-amino-acid splice variant/isoform of the native follistatin protein.

Direct human clinical data on injectable recombinant Follistatin 344, as sold by research-peptide suppliers, is sparse to essentially nonexistent. Almost everything known about follistatin's effect on muscle mass comes from animal models — most famously myostatin-knockout and follistatin-overexpressing transgenic mice — and from in vitro work. Where human data does exist, it comes from a very different context: gene therapy trials delivering the follistatin gene via an adeno-associated virus (AAV) vector in neuromuscular disease, not from injections of the FST344 protein itself. That distinction matters — AAV gene therapy produces sustained local expression from a single treatment, which is pharmacologically very different from a bolus of injected recombinant protein with a short circulating half-life.

Clinical & Research Status

Important distinction: the human trials that exist used AAV1-delivered follistatin gene therapy, administered by intramuscular injection of a viral vector that causes the muscle to produce its own follistatin over time. This is a fundamentally different exposure profile from injecting recombinant FST344 protein directly, which is rapidly cleared from circulation. No human trial has evaluated injectable FST344 protein as sold on the research-peptide market.

Mechanism of Action

Follistatin binds and neutralises myostatin (GDF-8) and activin A. Both of these signalling proteins normally act as negative regulators of skeletal muscle growth, signalling through the activin type IIB receptor (ActRIIB) and the downstream SMAD2/3 pathway to restrain muscle protein synthesis and satellite cell activation. By sequestering myostatin and activin, follistatin relieves this inhibitory brake — theoretically permitting increased muscle protein synthesis, satellite cell activity, and hypertrophy.

Research Areas & Reported Effects

Skeletal Muscle Hypertrophy (Preclinical)

The foundational reference point for follistatin's muscle-building reputation is the mouse literature: myostatin-null mice and follistatin-overexpressing transgenic mice show dramatic increases in muscle mass — the classic "mighty mouse" phenotype. This preclinical work established the myostatin/follistatin axis as one of the most potent known regulators of muscle mass in mammals.

Muscular Dystrophy Gene Therapy Research (Human)

The clearest human evidence involving follistatin comes from AAV1-follistatin gene therapy trials conducted in Becker muscular dystrophy and sporadic inclusion body myositis, led by groups including Mendell JR and colleagues at Nationwide Children's Hospital. These were small Phase 1/2a trials assessing safety and functional outcomes, and again, used a gene therapy delivery route rather than an injectable protein.

Reproductive and Ovarian Function Research

Follistatin was originally discovered in a reproductive endocrinology context, as a protein that binds activin and regulates follicle-stimulating hormone (FSH) secretion and ovarian follicle development. This is foundational endocrinology, not muscle-building research, but it is relevant to understanding follistatin's broader biological role beyond skeletal muscle.

Fibrosis Research (Preclinical)

Because activin and TGF-beta signalling are implicated in fibrotic disease processes, follistatin-mediated inhibition of this pathway has been studied in preclinical fibrosis models. This remains an early-stage, non-clinical research area.

Research Data Summary

Stack Combinations Studied

• No controlled human research exists studying injectable FST344 in combination with other peptides or growth-hormone secretagogues.
• Preclinical work has examined the myostatin/follistatin axis alongside other growth-regulating pathways (e.g. IGF-1 signalling) in animal models, but not as a "stack" in the research-peptide-community sense.

⚠️ Stack combinations listed for research reference only. Not safety or efficacy guidance.

Research Protocol Reference

Preclinical and gene-therapy trial protocols only — not dosing recommendations, and not applicable to injectable FST344 products.

Observed Side Effects in Research

• In the small AAV1-follistatin gene therapy trials (Becker MD / inclusion body myositis): injection/infusion site reactions were reported; no major systemic adverse events were reported in these small cohorts
• Theoretical concern (mechanism-based, not established from FST344-specific human trial data): effects on reproductive hormone regulation, given activin's established role in FSH signalling
• Theoretical concern (mechanism-based): cardiac or fibrotic tissue signalling effects, given the TGF-beta superfamily's broader role in cardiac remodelling — this is a caution derived from biology, not a documented adverse event from injectable FST344 trials, because that trial data largely does not exist

It is important to be direct about the evidence gap here: because there is essentially no published human trial data on injectable recombinant FST344 protein as sold on the research-peptide market, side-effect claims specific to that product and route cannot be responsibly made either way. The theoretical concerns above come from understanding the myostatin/activin/TGF-beta pathway, not from documented trial outcomes of the injectable FST344 product itself.

Compound Data

CAS Number

Not consistently assigned — as a recombinant protein, Follistatin is classified by UniProt/sequence identity rather than the small-molecule CAS registry. UniProt reference: P19883 (human Follistatin precursor)

Molecular Formula

Not applicable — large recombinant glycoprotein, not expressed as a small-molecule chemical formula

Molecular Weight

~35 kDa (FST344 isoform; non-glycosylated core approximately 34–38 kDa depending on glycosylation)

Half-Life

Short in circulation — approximately minutes to a few hours; rapid clearance is a recognised practical limitation for injectable protein research use

Synonyms

FST344, Follistatin-344, Activin-binding protein

Research Classification

Myostatin/activin-binding glycoprotein, TGF-beta superfamily antagonist

Scientific References

• Lee SJ, McPherron AC [2001] — Regulation of myostatin activity and muscle growth. — Proceedings of the National Academy of Sciences (PNAS) — [Transgenic/knockout mouse model]
• Mendell JR, Sahenk Z, Al-Zaidy S, et al. [2015] — A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy and sporadic inclusion body myositis. — Molecular Therapy — [Human Phase 1/2a gene therapy trial]
• Ueno N, Ling N, Ying SY, et al. [1987] — Isolation and partial characterization of follistatin. — Proceedings of the National Academy of Sciences (PNAS) — [Foundational discovery paper]
• Zimmers TA, Davies MV, Koniaris LG, et al. [2002] — Induction of cachexia in mice by systemically administered myostatin. — Science — [Mechanistic mouse model]
• Kota J, Handy CR, Haidet AM, et al. [2009] — Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. — Science Translational Medicine — [Preclinical nonhuman primate study]

This compliance check is automated and does not constitute legal advice. No Nonsense Fitness recommends independent legal review for all published content.